Flavia Nelson, MD

Articles by Flavia Nelson, MD

Practice Pearls for Management of NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 26th 2023

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

The Unmet Needs in NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 26th 2023

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Approaches to NMOSD Treatment in Clinical Practice

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 26th 2023

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Use of FDA Approved Disease-Modifying Therapies vs Other Treatments in NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 19th 2023

Neurology experts expand on advantages and disadvantages of using FDA-approved treatment compared with other therapy options for neuromyelitis optica spectrum disorder.

Effects of Polymorphism in the Use of Anti-CD19 and Anti-CD20 B-cell Therapy in NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 19th 2023

Robert Shin, MD, FAAN, discusses the potential advantages of using inebilizumab over rituximab in the treatment of NMOSD.

Safety Considerations for Therapies in NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 12th 2023

With a plethora of new treatments for NMOSD, a panel discusses safety concerns.

Recent Approvals for NMOSD Treatment

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 12th 2023

Experts in neurology discuss newly approved medications in the treatment of neuromyelitis optica spectrum disorder, including inebilizumab, eculizumab, and satralizumab.

Treatment Selection in NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 5th 2023

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller discuss the current neuromyelitis optica spectrum disorder treatment landscape.

Initiating Treatment and Goals of Therapy for NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

April 5th 2023

Expert neurologists review treatment goals in patients with neuromyelitis optica spectrum disorder and share insights on long-term disease-modifying therapies.

Progression of NMOSD Over Time

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

March 29th 2023

Experts in neurology discuss the progression of neuromyelitis optica spectrum disorder, focusing on acute relapse and pseudo attacks.

Pathophysiology of NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

March 29th 2023

Aaron Miller, MD, FAAN, reviews the pathophysiology of neuromyelitis optica spectrum disorder and the role of aquaporin-4 in the disease pathway.

Differential Diagnosis and Types of NMOSD

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

March 22nd 2023

Flavia Nelson, MD, and Robert Shin, MD, FAAN, provide insight on the forms of neuromyelitis optica spectrum disorder and how its attacks differ from multiple sclerosis.

Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)

ByBrian G. Weinshenker, MD,Flavia Nelson, MD,Robert Shin, MD, FAAN,Aaron Miller, MD, FAAN

March 22nd 2023

Aaron Miller, MD, FAAN, provides an overview of neuromyelitis optica spectrum disorder (NMOSD).

Practice Pearls for the Management of Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

August 10th 2022

Experts in neurology share practice pearls to optimize the treatment for patients with multiple sclerosis.

Emerging Therapies and Future Directions in MS

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

August 10th 2022

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their excitement for the future of multiple sclerosis treatment and comment on emerging therapies.

Treatment Sequencing in Patients With Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

August 10th 2022

Experts in neurology provide insight into treatment selection and sequencing in patients with multiple sclerosis, focusing on S1P modulators.

Using Neurofilaments as a Biomarker in MS

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

August 3rd 2022

Dr Jacqueline Nicholas hypothesizes about the utility of neurofilaments as a biomarker of disease severity in patients with multiple sclerosis.

Safety Considerations and Monitoring for S1P Modulators in MS

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

August 3rd 2022

Heidi Crayton, MD, and Jacqueline Nicholas, MD, review the importance of long-term safety data in the management of patients with multiple sclerosis, and Flavia Nelson, MD, discusses her approach to counseling patients on the safety considerations regarding new S1P modulating agents.

Impact of S1P Modulators on Brain Volume Measures in Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 27th 2022

Dr Flavia Nelson comments on the impact of S1P modulators on brain volume measures; highlighting thalamic atrophy and its correlation with brain volume loss in MS.

Efficacy and Safety of S1P Receptor Modulators in Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 27th 2022

Experts in neurology review data surrounding the role of disease-modifying therapies in preventing grey matter brain atrophy and cognitive decline.

The Role of S1P Modulators in Multiple Sclerosis Management

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 20th 2022

Dr Heidi Crayton discusses the role of S1P receptor modulators in the management of patient with multiple sclerosis.

Overview of Brain Atrophy Data and Cognition Research in MS

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 20th 2022

Flavia Nelson, MD, provides an overview of available brain atrophy data and cognition research in patients with multiple sclerosis.

Brain Health Assessment Challenges in MS

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 13th 2022

Jacqueline Nicholas, MD, provides insight into challenges inherent to the assessment of brain health in patients with multiple sclerosis [MS].

The Role of Imaging in the Assessment of Brain Health and Cognition

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 13th 2022

Heidi Crayton, MD, shares a patient story to highlight the importance of imaging modalities in identifying brain loss and atrophy in patients with multiple sclerosis [MS].

Initiating Conversations Around Cognitive Health for Patients With MS

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 6th 2022

Experts in neurology comment on the level of patient awareness surrounding cognitive decline in multiple sclerosis and highlight how to engage patients in difficult conversations regarding their cognitive health.

Cognitive Dysfunction Clinical Assessments for Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

July 6th 2022

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their practices and diagnostic assessments for cognitive decline in their patients with multiple sclerosis.

Cognitive Decline Presentation in Patients With Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

June 29th 2022

Experts in neurology discuss the multiple ways in which cognitive decline can present in their patients with multiple sclerosis and highlight how they assess for it.

Overview of Multiple Sclerosis

ByStephen Krieger, MD,Heidi Crayton, MD,Jacqueline Nicholas, MD, MPH,Flavia Nelson, MD

June 29th 2022

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, provide an overview of multiple sclerosis shedding light on the clinical course of disease.